Welcome to our dedicated page for Hologic news (Ticker: HOLX), a resource for investors and traders seeking the latest updates and insights on Hologic stock.
Hologic, Inc. reports corporate-status and women’s health medical-technology developments following its acquisition by funds managed by Blackstone and TPG, which established Hologic as a private company. Its news has covered the completed transaction, governance changes, operating and financial results, and capital-structure matters tied to the former Nasdaq-listed common stock.
Company updates also describe Hologic’s diagnostics and cervical-health portfolio, including the Aptima HPV Assay, ThinPrep Pap Test and Genius Digital Diagnostics System, as well as public-health initiatives such as the Hologic Global Women’s Health Index and screening-awareness campaigns.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Hologic, Inc. (NASDAQ: HOLX) is set to release its financial results for Q2 2023 on May 1 after market close. A conference call will follow at 4:30 p.m. ET, where management will provide insights into the results. Interested participants can join the call by dialing the provided numbers or by click here to join. A replay will be available on Hologic's investor website.
Hologic, Inc. (NASDAQ: HOLX) will present at the Cowen 43rd Annual Health Care Conference on March 7, 2023, at 9:10 a.m. Eastern Time in Boston, MA. The conference runs from March 6-8 and includes various presentations and panel discussions on the health care industry. Hologic's presentation will be available via a live webcast on the company's investor website for 30 days post-event. Hologic is dedicated to enhancing women’s health through early detection and treatment innovations.